Live
- All-Party Committee Submits Memorandum to Sampath Kumar on Aiza Development Works.
- Rajnath Singh to join BJP's election campaign in J&K on Sunday
- Vadodara overbridge built in 2022 develops large potholes, residents demand action
- New Zealand ready to ‘adjust’ their game for Afghanistan Test match following red-ball hiatus
- Assam to intensify efforts to detect illegal Bangladeshi immigrants: Himanta Biswa Sarma
- After Putin, Italian PM Meloni says that India can resolve Russia-Ukraine conflict
- UP govt plans major upgrades for Baghpat and Muzaffarnagar sugar mills
- Special Pujas Held at Shree Ganapati Temple by Secunderabad Cantonment MLA Shree Ganesh for Vinayaka Chavithi
- Srinagar Colony urges officials to resolve overflowing drainage Issue
- Manolo Marquez warns fans about ‘reality’ of Indian football team ahead of Syria clash
Strides Pharma gets USFDA nod to market HIV drugHIV drug
Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
New Delhi: Strides Pharma Science on Wednesday said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.
Singapore-based Strides Pharma Global, a stepdown wholly-owned subsidiary of the company, has received approval for Efavirenz (600mg), Emtricitabine (200mg), Tenofovir Disproxil Fumurate (300mg), (EET) tablets from the US Food & Drug Administration (USFDA), the drug firm said in a statement. The company's product is bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC, it added. As per per IQVIA, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumurate tablet (EET) has a market opportunity of USD 7.5 million in the US. Shares of Strides Pharma Science ended 2.51 per cent up at Rs 508.20 apiece on the BSE on Wednesday
